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Abstract
Background: The efficacy and safety of various modes of medical treatment for primary hyperparathyroidism in
pregnancy are largely unknown.
Case presentation: We report the case of a 34-year-old white woman with primary hyperparathyroidism symptomatic
for nephrolithiasis. Her serum calcium was 3.15 mmol/l and parathyroid hormone was 109.0 ng/L. Neck imaging found
no pathological parathyroid tissue. Cinacalcet and cholecalciferol were started. She became pregnant 17 months later.
The calcimimetic was stopped. During pregnancy, she was admitted for hydration administered intravenously two to
three times per week. In her 24th week of pregnancy, cinacalcet was restarted. In her 32nd week, a cesarean section was
carried out as planned.
Conclusions: Only three cases of primary hyperparathyroidism in women on cinacalcet therapy in pregnancy
have been published in the literature. In the present case, hydration was useful in controlling serum calcium.
Cinacalcet therapy helped to control serum calcium.
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Background
Primary hyperparathyroidism (PHPT) is typically a dis-
ease of middle-aged and older women. A recent analysis
of a large health system database reported the incidence
of PHPT to be 4.7 to 6.2 cases per 100,000 person-years
in women of reproductive age (20 to 39 years) [1]. PHPT
usually runs a relatively benign clinical course. By con-
trast, during pregnancy PHPT may have serious clinical
implications [2], with rates of maternal complications,
fetal complications, and fetal/neonatal mortality being
estimated at 67 %, 80 % and 30 %, respectively [2, 3]. It
is therefore important to recognize this pathology during
pregnancy. This is not simple, however, owing to its
aspecific presentation [3]. The most frequent complica-
tions are hyperemesis, pre-eclampsia, nephrolithiasis,
pancreatitis, hypercalcemic crisis, intrauterine growth
retardation, preterm labor, neonatal tetany, and neonatal
death [2–4]. Although the pregnancy may develop
uneventfully, severe fetal/neonatal complications have
been reported even in cases of mild PHPT.
The optimal management of PHPT during pregnancy
needs to be individualized. Most authors advocate para-
thyroidectomy (PTx) as the treatment of choice [2].
Surgery should be performed in the second trimester
[3]. The safety of surgery in the first and third trimes-
ters is debated because of the associated risks for the
fetus [5]. The efficacy and safety of various modes of
medical treatment for PHPT in pregnancy are largely
unknown. So far, only hydration and calcitonin have
emerged as safe treatments [5], although both will
lower serum calcium (S-Ca) only temporarily. Bispho-
sphonates cross the placenta; they should therefore only
be used in emergencies as a short-term intervention
prior to surgery [6]. Calcimimetics are effective in redu-
cing S-Ca in PHPT; however, they have rarely been
used in pregnancy [7].
We describe a case of PHPT in pregnancy that was
treated with cinacalcet.* Correspondence: magius@unige.it
1Department of Internal Medicine, Genoa University, Viale Benedetto XV 6,
16132 Genoa, Italy
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Vera et al. Journal of Medical Case Reports  (2016) 10:361 
DOI 10.1186/s13256-016-1093-2
Case presentation
We report the case of a 34-year-old white woman with a
5-year history of nephrolithiasis, who was referred to the
Department of Endocrinology after having undergone a
previous endoscopic treatment. A biochemistry evalu-
ation revealed elevated S-Ca and parathyroid hormone
(PTH) levels, consistent with severe PHPT. All data
from the basic evaluation are reported in Table 1. She
had no family history of hypercalcemia or other factors
suggestive of multiple endocrine neoplasia (MEN) syn-
drome. Given her young age, genetic testing was per-
formed, which excluded MEN1 mutation. On examination,
no mass was palpable in her neck. Neck imaging revealed
no pathological parathyroid tissue: neck ultrasound,
technetium-99m (99mTc) sestamibi scan, and single-photon
emission computed tomography-computed tomography
(SPECT-CT). Neck ultrasound showed a small nodule of
10 mm in her right thyroid lobe. Her bone density is below
the expected range (Z-scores of −1.2 and −1.3 at her spine
and total hip, respectively). An abdominal ultrasound con-
firmed the bilateral presence of kidney stones. Oral hydra-
tion, cholecalciferol (600 U/day), vitamin C, and cinacalcet
were started, but calcimimetic therapy was poorly tolerated.
She became pregnant 17 months later while on therapy.
Given the unknown teratogenic effects of cinacalcet
in pregnancy, the calcimimetic was discontinued. Cho-
lecalciferol was continued to 1200 U daily. During
pregnancy, she presented two to three times per week
for saline infusions administered intravenously (sodium
chloride, NaCl, 0.9 % 1000 ml two to three times per
week) associated with oral hydration at home, but her
S-Ca level was not controlled. Conversely, her PTH
levels decreased (Table 2). Parathyroid re-exploration
was performed in her tenth week of gestation. A nodu-
lar area was found at the inferior pole of the left lobe;
the location and the sonographic appearance were typ-
ical of parathyroid adenoma. Fine-needle washing after
aspiration biopsy (PTH-FNAB) was therefore carried
out on both nodules. A cytological examination of the
left nodules was not diagnostic, but the PTH-FNAB
confirmed the thyroidal nature of the nodules:
thyroglobulin-fine-needle aspiration biopsy (FNAB)
41334.0 μg/l, calcitonin-FNAB 6.8 ng/l, and PTH-
FNAB 4.0 ng/l. The right nodule was a colloid nodule,
which was classified according to the British Thyroid
Association as Thy2: thyroglobulin-FNAB 23690.0 μg/l,
calcitonin-FNAB 6.3 ng/l, and PTH-FNAB 4.0 ng/l. Ex-
ploratory surgery was proposed in her second trimester
of pregnancy, but was refused and postponed to the
postpartum period. Options for medical management
were therefore explored. In her 24th week of gestation,
daily treatment with cinacalcet (15 to 30 mg/day orally)
was restarted, but nausea and hyperemesis ensued.
The combination of calcimimetic and intravenously
administered hydration resulted in a small decrease in
her S-Ca (Table 2). However, in her 25th week, an
episode of renal pain due to left nephrolithiasis oc-
curred. Her renal function was normal, as was her
electrocardiogram-monitored cardiac function.
She was hospitalized in her 30th week of pregnancy
for a non-serious spontaneous rupture of the mem-
branes. A preterm delivery was decided upon. In her
32nd week of pregnancy, a cesarean section was carried
out, and a baby boy was delivered. Postpartum, she dis-
continued cinacalcet in order to start breastfeeding. She
was discharged on postoperative day 3, as is normal. A
blood test 8 weeks after her cesarean section revealed
elevated S-Ca and PTH levels, as noted in her pre-
pregnancy period. Breastfeeding was discontinued and
cinacalcet was restarted. The time-course of her S-Ca
during pregnancy and her puerperium are reported in
Fig. 1.
One year after delivery, she underwent surgical explor-
ation of her neck without further localization studies.
Ten minutes after surgical removal of her left upper
parathyroid gland (1.2 cm), her level of intraoperative
PTH was 22 pg/ml. One day after PTx, her S-Ca levels
were 2.22 mmol/L. Histology confirmed the diagnosis of
adenoma of the parathyroid gland.
The neonate
Ultrasound scans in her first and second trimesters
revealed normal fetal development. Immediately after
delivery, the baby boy (weight 2.03 kg; length 45.0 cm;
Table 1 Laboratory findings on diagnosis, during pregnancy, and postpartum (median values are reported)
Diagnosis Pregnancy Puerperium Normal range
Creatinine (mg/dl) 0.7 0.8 0.8 0.5–1.3
GFR (ml/minute/1.73m2) >60.0 107.0 107.0 >60.0
Ca(U) (g/24 hours) 0.46 0.35 – 0.05–0.40
S-Ca (mmol/l) 3.15 3.025 3.0 2.12–2.75
S-P (mg/dl) 1.6 1.9 1.9 2.5–4.5
PTH (ng/l) 109.0 44.0 124.0 6.5–36.5
25OHvitD (ng/ml) 20.1 21.0 13.5 >30.0
GFR glomerular filtration rate, Ca(U) urinary calcium, S-Ca serum calcium, S-P serum phosphorous, PTH parathyroid hormone, 25OHvitD 25hydroxyvitamin D
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head circumference 31.7 cm, Apgar score 8 to 9) was
transferred to our neonatal intensive care unit. The baby
boy had hyperphosphatemia with serum phosphorous
(S-P) of 7.94 mmol/l, hypocalcemia with ionized calcium
(Ca++) of 1.12 mmol/l, and low PTH (17.0 ng/l); a pic-
ture compatible with hypoparathyroidism due to mater-
nal hyperparathyroidism. Therefore, oral calcium
gluconate 10 % (3 ml×7/day = 100 mg/kg) and vitamin
D (ergocalciferol, two drops/day and alfacalcidol, two
drops/day) in milk feed were started. A mild episode of
neonatal tetany occurred in week 4. After 6 weeks, cal-
cium supplementation was stopped and serum Ca++ was
stable (Ca++ 1.13 mmol/l; S-Ca 3.61 mmol/l). His PTH
(38.0 ng/l) and S-P (7.12 mmol/l) were in the normal
range. The time-course of Ca++ (in the first 30 days
postpartum) is reported in Fig. 2.
Discussion
During pregnancy, the calcium metabolism is altered in
order to supply calcium to the fetus. Although S-Ca may
decrease owing to lower levels of albumin, Ca++ remains
constant. In order to meet fetal needs, intestinal calcium
absorption doubles under mediation by calcitriol, prolac-
tin, and placental lactogen. There is a compensatory
increase in renal calcium excretion, which allows the
mother to remain eucalcemic. By contrast, in our case,
S-Ca increased considerably, while urinary calcium
remained in the normal range, probably owing to a dilu-
tion effect induced by forced hydration. Changes in
PTH, PTH-related protein (PTHrP), calcitonin, and
calcitriol may occur throughout pregnancy, but typically
do not produce clinically significant perturbations in cal-
cium balance [8].
Pathologic alterations in calcium metabolism during
pregnancy are uncommon, but include PHPT, milk-
alkali syndrome or PTHrP-mediated hypercalcemia [9].
During pregnancy and the puerperium, sources of
PTHrP include underlying malignancy, placenta, and
mammary tissue during lactation: cases have been re-
ported of hypercalcemic crises attributable to each of
these sources [10]. Since PTH levels are not proportion-
ately high, the poor control of hypercalcemia may be
partly a result of PTHrP. After delivery, hypercalcemia
may acutely worsen owing to loss of placental shunting
of calcium away from the maternal circulation; alterna-
tively, S-Ca levels may decrease if the placenta was a
source of PTHrP, which may have been a factor in our
case.
As demonstrated by our patient, PHPT may put the
mother and fetus at risk of more severe complications;
this case also illustrates the fact that maternal hypercal-
cemia can cause neonatal hypoparathyroidism, which are
manifested in only 12 % of neonates [11].
Considerations on imaging
The usual techniques for detecting parathyroid adenomas
or hyperplasias are not recommended in pregnancy. Tech-
netium (Tc) and 99mTc sestamibi scintigraphy should be
avoided, owing to the risk of ionizing radiation for the
Table 2 The time-course of serum calcium and parathyroid hormone levels and treatment in a patient with primary hyperparathyroidism
Time Treatment Serum calcium (mmol/l) Parathyroid hormone (ng/L)
1st trimester NaCl 0.9 % 1000 ml i.v. 2/week 3.025–3.775 48.0
2nd trimester NaCl 0.9 % 1000 ml i.v. 3/week 2.800–3.325 44.0–62.0
3rd trimester Cinacalcet 15–30 mg/day 2.775–3.125 –
Postpartum No therapy 2.900–3.000 46.0–124.0
i.v. intravenous, NaCl sodium chloride
Fig. 1 Serum calcium levels in the patient. The graph shows the
effect of treatments on the patient’s serum calcium levels during
pregnancy and puerperium. i.v. intravenous, S-Ca serum calcium
Fig. 2 Serum calcium levels in the baby boy. The graph shows the
effect of treatments on serum ionized calcium levels in the baby
boy in the first 30 days postpartum. Ca++ ionized calcium
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fetus. The effects of fetal irradiation are divided into deter-
ministic effects (caused by damage to a number of cells in
tissues) and stochastic effects (caused by mutations in
cells). McMullen et al. [12] have described the use of func-
tional imaging in pregnancy while appropriately shielding
the fetus; in our case, however, such an approach would
have been very unlikely to yield a positive result, as the
SPECT-CT performed shortly before the pregnancy was
negative. In addition, McMullen et al. [12] claimed that
99mTc sestamibi imaging may be used safely to visualize
the parathyroid glands only after negative cervical ex-
plorations, which our patient had refused. Thus, neck
ultrasound is currently the first-line investigation for
locating parathyroid diseases during pregnancy (sensi-
tivity of 69 %, specificity of 94 %) [3, 13]. The failure of
imaging is most unusual in patients with S-Ca levels
higher than 3 mmol/L, as in our case. In our case, an
ultrasonography examination was supplemented by
PTH-FNAB. The use of this type of examination in the
diagnosis of PHPT is debated [14]. In the present case,
however, it was necessary in order to tackle the differ-
ential diagnosis between PHPT and thyroid nodules
and then to decide whether to undertake mini-invasive
surgery (recommended) or exploratory surgery (more
invasive and therefore not recommended in pregnancy)
[12]. Sometimes a mediastinal parathyroid adenoma is
the culprit, but pre-pregnancy SPECT-CT had excluded
this in our patient.
Finally, computed tomography (CT) and MRI were
not performed because when they are used alone they
are relatively insensitive in detecting normally located
and ectopic parathyroid adenomas [12]. In Italy, positron
emission tomography (PET) with methionine has only
recently been proposed for the localization of parathy-
roid glands, and was therefore not performed in our pa-
tient before pregnancy.
Considerations on treatment
Surgery is the first choice of treatment in patients with
symptomatic PHPT. Minimally invasive approaches have
gained progressive acceptance as an alternative safe and
effective technique over the past two decades, owing to
the use preoperative imaging to suggest the position of
the parathyroid glands [15]. Although negative im-
aging studies would not preclude neck exploration in a
young woman with moderately severe hypercalcemia
and recurrent nephrolithiasis, our patient chose to
postpone neck exploration with the more invasive
techniques required for PTx; medical treatment was
therefore initiated. However, bone anti-reabsorptive
therapy was not started because her bones had not
been significantly compromised.
There are no guidelines for the treatment of PHPT in
pregnancy. The options are a conservative approach or
surgery [3]. Both approaches carry the risk of drug-
related side effects and procedure-related side effects,
although the risk imposed by hypercalcemia is some-
times greater. PTx is the only curative treatment, but is
recommended only when medical treatment is insuffi-
cient [3]. If surgery is deferred, as in our case, it should
be undertaken as soon as possible after delivery, to pre-
vent a hypercalcemic crisis.
Conservative management has been shown to signifi-
cantly reduce maternal and fetal complications [3].
Intravenously or orally administered rehydration, with or
without forced diuresis, is the first line of treatment [11].
In our case, we first started hydration without forced di-
uresis because the patient was hypotensive (her mean
arterial pressure was 65 to 70 mmHg). However, as sa-
line therapy administered intravenously is very unlikely
to have a lasting benefit in any patient, close maternal
and fetal monitoring are necessary in order to prevent
clinical or biological deterioration. As calcitonin alone is
considered ineffective for long-term S-Ca control, it was
not administered in this case. As bisphosphonates are
embryotoxic [16], they are not recommended. The use
of cinacalcet during pregnancy is debated [3]. However,
as S-Ca levels were still very high in our patient, cinacal-
cet seemed the best choice. Unfortunately, our case
seems to indicate that the use of cinacalcet to treat
PHPT in pregnancy is not effective in the acute control
of S-Ca. In fact, evidence for a true benefit of cinacalcet
in our case is very weak. Moreover, we do not know
whether this caused a premature decline in S-Ca or
compromised fetal calcium metabolism. Before consider-
ing cinacalcet treatment, we extensively discussed the
pros and cons, as its use in pregnancy has been scantly
reported.
Review of the literature
Since the first case of PHPT in pregnancy was reported
in 1932 [4], about 200 cases have been published in the
medical literature. Moreover, only three cases of PHPT
in women on cinacalcet therapy in pregnancy [8, 17, 18]
and two cases in puerperium [17, 19] have been pub-
lished. Horjus et al. [17] first described a case of PHPT,
while Edling et al. [8] described a case of parathyroma-
tosis and Nadarasa et al. [18] reported a case of carcin-
oma. In the first two cases, therapy was initiated during
the third trimester, whereas in our case we decided to
start at the end of the second trimester, given the lack of
control of S-Ca. In the third case, pregnancy was initi-
ated while the patient was on calcium-lowering therapy,
as in our case. In the cases previously reported, toler-
ance was variable, whereas in our case it was poor, thus
precluding administration at higher doses. In our case,
unlike those reported in the literature, it was not
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possible to perform PTx. Therefore, cinacalcet was
restarted in the puerperium [17, 19].
Conclusions
Only three cases of PHPT in women on cinacalcet ther-
apy in pregnancy have been published in the medical lit-
erature. Hydration was useful in controlling S-Ca, and
cinacalcet therapy also helped to control S-Ca, although
it was dangerously high. However, in the present case,
evidence for a true benefit of cinacalcet is very weak. In
our case, cinacalcet tolerance was very poor, which pre-
cluded the administration of higher doses. It remains
unclear whether PTH levels in pregnancy were reduced
owing to a possible role of placental PTHrP.
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